GLENMARK PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 532296     NSE : GLENMARK    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : None or < 25%
May 20,2022
Price(EOD): β‚Ή 407.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: β‚Ή 11,496.83 Cr
Value of β‚Ή 1 Lac invested in GLENMARK PHARMACEUTICALS
on May 22,2017 (price: β‚Ή 668.65)

β‚Ή 1 L

β‚Ή 0.61 L

1W : 3.8% 1M : -10.9% 1Y : -35.5%
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results
GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Top Undervalued Mid Cap Stocks
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 3.8% -10.9% -35.5%
SUN PHARMACEUTICAL INDUSTRIES 3.4% -0.8% 28%
DIVIS LABORATORIES 2.1% -3.3% 4.4%
DR REDDYS LABORATORIES 9.2% -1.1% -24.4%
CIPLA 4.9% -3.3% 6.1%
GLAND PHARMA -1.3% -6.3% 1%
PIRAMAL ENTERPRISES 2.3% -13.7% 12%
CADILA HEALTHCARE 3.5% -0.9% -44%
TORRENT PHARMACEUTICALS 3.1% -6.9% -4.9%

FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Dec2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF GLENMARK PHARMACEUTICALS

 
Valuation Score
[As on : May 20,2022 ]

Ratio Consolidated
P/E
P/B
P/S
11.85
P/E Calculated based on EPS of 34.38
[ Mar2021 - Consolidated Results ]

1.63
P/B Calculated based on Book Value of 249.6
[ Mar2021 - Consolidated Results ]

0.95
P/S Calculated based on Revenues of 12145.7 Cr
[ TTM - Consolidated Results ]

Financial Ratios →

Insights πŸ’‘ GLENMARK is one of the potential top 20% undervalued companies ! Discover More →

FAIR VALUE OF GLENMARK PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-60%
-68%
-66%

Insights πŸ’‘ You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS


Insights πŸ’‘ There are 7% companies with bullish price momentum currently! Discover More →

GLENMARK PHARMACEUTICALS vs SENSEX


Insights πŸ’‘ You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF GLENMARK PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.25
0.27
0.26
0.26
0.67
0.8
0.8
0.76
[Last Annual Data : Mar2021]
Financial Ratios →

PLEDGED PROMOTER SHARES OF GLENMARK PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Mar2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF GLENMARK PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
0.83%
17.45%
-10.89%
-12.76%
13.87%
30.77%
-1.42%
-3.4%
QtrlyTrend
0
Latest Qtr: Dec2021
Quarterly Result Analysis →


GLENMARK PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE MIDSMALLCAP 3.7% -8.4% 12.6%
S&P BSE 400 MIDSMALLCAP 3.6% -7.9% 11.9%
S&P BSE 150 MIDCAP 3.3% -7% 11.5%
S&P BSE ALLCAP 3.2% -5.8% 10.3%
S&P BSE MID CAP 3.2% -8% 8%
S&P BSE 500 3.2% -5.6% 9.7%
S&P BSE LARGE MIDCAP 3.1% -5.2% 9.2%
S&P BSE 250 LARGEMIDCAP 3.1% -5.3% 9.5%
S&P BSE HEALTHCARE 2.8% -6.4% -4.8%
NSE Indices1W1M1Y
NIFTY PHARMA 3.5% -3.4% -5.7%
NIFTY MID SMALL400 3.4% -8% 12.5%
NIFTY500 MULTICAP 50:25:25 3.4% -6.8% 11%
NIFTY 500 3.1% -5.7% 9.7%
NIFTY HEALTHCARE 3% -6.2% -3.4%
NIFTY 200 3% -5.3% 9.3%
NIFTY LARGE MIDCAP 250 3% -6% 10.5%
NIFTY MIDCAP150 2.9% -7.1% 12%
NIFTY FREE MIDCAP 100 2.9% -7.3% 12.3%

You may also like the below Video Courses


FAQ about GLENMARK PHARMACEUTICALS


Is GLENMARK PHARMACEUTICALS good for long term investment?

As on May 20,2022, the Fundamentals of GLENMARK PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is GLENMARK PHARMACEUTICALS UnderValued or OverValued?

As on May 20,2022, GLENMARK PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of GLENMARK PHARMACEUTICALS ?

As on May 20,2022, the Intrinsic Value of GLENMARK PHARMACEUTICALS is Rs. 1,201.67 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,021.86
Fair Value [Median EV / Sales Model] : Rs. 1,276.50
Fair Value [Median Price / Sales Model] : Rs. 1,201.67
Median Fair Value of GLENMARK PHARMACEUTICALS : Rs. 1,201.67

Is GLENMARK PHARMACEUTICALS trading at a Premium or Discount?

As on May 20,2022, GLENMARK PHARMACEUTICALS is trading at a Discount of -66% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z
ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z